Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) saw a significant drop in short interest in May. As of May 15th, there was short interest totaling 2,664 shares, a drop of 45.1% from the April 30th total of 4,855 shares. Based on an average trading volume of 16,063 shares, the short-interest ratio is presently 0.2 days.
Humacyte Stock Performance
NASDAQ:HUMAW traded down $0.00 during mid-day trading on Thursday, hitting $0.05. 1,000 shares of the stock traded hands, compared to its average volume of 15,161. Humacyte has a 52 week low of $0.04 and a 52 week high of $0.60. The firm’s 50 day moving average is $0.08 and its two-hundred day moving average is $0.11.
About Humacyte
Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.
Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.
Read More
- Five stocks we like better than Humacyte
- Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
- Gen Z Trends Make These 3 Stocks Worth Watching
- How the Memory Shortage Is Crushing the Gaming Industry
- Ulta’s Q1 Report Primes It for a Beauty of a Rebound
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
